

Can't find Paxlovid 150 Mg /100 Mg Dose Pack at your pharmacy? Use these tools and tips to locate it in stock near you quickly in 2026.
You have a prescription for Paxlovid 150 Mg /100 Mg Dose Pack, but your pharmacy says they don't have it. With COVID-19 antivirals, every hour counts — Paxlovid needs to be started within 5 days of symptom onset to work effectively. So what do you do?
In this guide, we'll walk you through practical tools and tips to find Paxlovid 150 Mg /100 Mg Dose Pack in stock near you as quickly as possible.
The fastest way to find Paxlovid in stock is to use Medfinder. Medfinder is a free tool that shows you which pharmacies near your location currently have your medication available. Instead of spending time calling pharmacy after pharmacy, you can search online and see results instantly.
Here's how it works:
This is especially useful for the renal dose pack, which is stocked in smaller quantities than the standard Paxlovid formulation.
When large chain pharmacies are out of stock, independent pharmacies can be a lifesaver. Here's why:
You can also try specialty pharmacies that focus on infectious disease medications. These pharmacies are more likely to stock Paxlovid in multiple formulations.
Pharmacy phone lines get slammed during COVID surges, especially in the morning. Try calling in the early afternoon or later in the evening. You'll spend less time on hold and have a better chance of reaching a pharmacist who can check their inventory and help you directly.
Another tip: if you're visiting a pharmacy in person, going during less busy hours (mid-afternoon on weekdays) can give you more face time with the pharmacist, who may be able to check nearby locations or call their wholesaler for you.
If you've tried the steps above and still can't locate the 150 Mg /100 Mg Dose Pack, here are a few more options:
Your prescriber can transfer your prescription to a pharmacy that has Paxlovid in stock. If you've found availability through Medfinder, share the pharmacy name and address with your doctor's office so they can send the script directly.
Pfizer's PAXCESS support line can help you locate pharmacies with Paxlovid in stock. They can also connect you with financial assistance through the PAXCESS Co-Pay Savings Program or the U.S. Government Patient Assistance Program if cost is an issue.
If Paxlovid is truly unavailable, your doctor may recommend an alternative COVID-19 treatment. Remdesivir (Veklury) is a first-line IV alternative, and Molnupiravir (Lagevrio) is an oral second-line option. Both are approved for high-risk patients with mild-to-moderate COVID-19.
If you don't already have a prescription, telehealth services can connect you with a provider quickly — often within hours. Services like Amazon One Medical, Doctor On Demand, and state health department telehealth programs can evaluate you for COVID-19 treatment and send a Paxlovid prescription directly to a pharmacy that has it in stock. Learn more in our guide on how to find a doctor who can prescribe Paxlovid.
Finding Paxlovid 150 Mg /100 Mg Dose Pack can take some extra effort, but the medication is available if you know where to look. Start with Medfinder to check real-time availability, branch out to independent pharmacies, and don't hesitate to ask your doctor for help transferring your prescription.
Time matters with Paxlovid. The sooner you start treatment, the better your chances of avoiding severe COVID-19. Don't give up — use the tools and tips in this guide to get your medication as quickly as possible.
For more information, read our Paxlovid shortage update for 2026.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.